ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking on the Signs and Symptoms of Bullous Keratopathy (C3R)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01106274
Recruitment Status : Completed
First Posted : April 19, 2010
Last Update Posted : April 19, 2010
Sponsor:
Information provided by:
Mashhad University of Medical Sciences

Brief Summary:
Recently, riboflavin (0.1%) and ultraviolet-A (UVA) collagen cross-linking (C3R) has shown potential to improve the signs and symptoms of bullous keratopathy .The objective of this study is to demonstrate the effects of C3R to treat bullous keratopathy.

Condition or disease Intervention/treatment Phase
Bullous Keratopathy Radiation: ultraviolet-A Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of the Effects of Riboflavin/ Ultraviolet-A Corneal Cross-linking
Study Start Date : November 2008
Actual Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Riboflavin
U.S. FDA Resources


Intervention Details:
    Radiation: ultraviolet-A
    Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • patients with bollous keratopathy

Exclusion Criteria:

  • corneal scarring or contemporary eye disease affecting VA were excluded.

ClinicalTrials.gov Identifier: NCT01106274     History of Changes
Other Study ID Numbers: MUMS-88191
First Posted: April 19, 2010    Key Record Dates
Last Update Posted: April 19, 2010
Last Verified: October 2008

Additional relevant MeSH terms:
Corneal Edema
Corneal Diseases
Eye Diseases
Riboflavin
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Photosensitizing Agents
Dermatologic Agents